TY - JOUR
T1 - Thrombopoietin Receptor Agonists
T2 - A Critical Review
AU - Mitchell, William B.
AU - Bussel, James B.
N1 - Publisher Copyright:
© 2014 Elsevier Inc.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging. The purpose of this review will be to focus critically on what we know or do not know at this point about these agents. We review the evolution, efficacy and clinical use, side effects, special populations, and off-target effects of the thrombopoietic agents.
AB - Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging. The purpose of this review will be to focus critically on what we know or do not know at this point about these agents. We review the evolution, efficacy and clinical use, side effects, special populations, and off-target effects of the thrombopoietic agents.
UR - http://www.scopus.com/inward/record.url?scp=84920670950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920670950&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2014.11.001
DO - 10.1053/j.seminhematol.2014.11.001
M3 - Review article
C2 - 25578419
AN - SCOPUS:84920670950
SN - 0037-1963
VL - 52
SP - 46
EP - 52
JO - Seminars in hematology
JF - Seminars in hematology
IS - 1
ER -